Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Other Non-Current Liabilities (2016)

Historic Other Non-Current Liabilities for RedHill Biopharma (RDHL) over the last 6 years, with Q4 2016 value amounting to $1.1 million.

  • RedHill Biopharma's Other Non-Current Liabilities changed 0.0% to $1.1 million in Q4 2016 from the same period last year, while for Dec 2016 it was $1.1 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $1.1 million for FY2016, which is 0.0% changed from last year.
  • RedHill Biopharma's Other Non-Current Liabilities amounted to $1.1 million in Q4 2016, which was down 0.0% from $1.1 million recorded in Q3 2016.
  • Over the past 5 years, RedHill Biopharma's Other Non-Current Liabilities peaked at $3.3 million during Q4 2012, and registered a low of $1.1 million during Q1 2015.
  • Its 5-year average for Other Non-Current Liabilities is $1.7 million, with a median of $1.5 million in 2014.
  • Per our database at Business Quant, RedHill Biopharma's Other Non-Current Liabilities soared by 2185.41% in 2012 and then plummeted by 5272.28% in 2014.
  • RedHill Biopharma's Other Non-Current Liabilities (Quarter) stood at $3.3 million in 2012, then plummeted by 42.96% to $1.9 million in 2013, then decreased by 18.16% to $1.5 million in 2014, then plummeted by 30.82% to $1.1 million in 2015, then changed by 0.0% to $1.1 million in 2016.
  • Its Other Non-Current Liabilities stands at $1.1 million for Q4 2016, versus $1.1 million for Q3 2016 and $1.1 million for Q2 2016.